Ticagrelor (Brilinta 90 mg) and Darunavir: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
The boosted regimen increases ticagrelor or reduces clopidogrel active-metabolite exposure.
Clinical significance and safety
For ritonavir-boosted darunavir (PREZISTA/ritonavir), ticagrelor and clopidogrel are not recommended. The risks differ: ticagrelor exposure may increase, while clopidogrel antiplatelet activity may decrease; the prescriber must select an appropriate plan.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.